The Bravest Thing a CEO Can Say Is "I Don't Know" with Renee Ryan

In this episode of the Crux of Neuro, Renee Ryan, co-founder and CEO of PinPrint and former CEO of Cala Health. Renee traces her path from Wall Street healthcare banker to one of medtech’s most prolific investors and operators. She explains why, in neurotech today, getting reimbursed is often harder than getting cleared and how data became the whole story.Key TopicsRenee’s path from healthcare investment banking to leading J&J’s medtech investing (JJDC)Founding Verb Surgical and investing across J&J’s surgical-robotics portfolio (Auris, Verb)Crossing from investor to operator as CEO of Cala HealthWinning Medicare coverage for wearable, at-home neuromodulationLaunching PinPrint and high-resolution 3D-printed microneedle patchesRelated InsightsWhy “if it’s not published, it doesn’t exist” to payersHow a connected device turns real-world data into reimbursement evidenceThe shift in medtech from “get FDA approval” to “prove you can get paid”Pharma and medtech converging around sensors, biomarkers and real-time dataCore ChallengesWearable, at-home neuromodulation didn’t fit existing reimbursement codes forcing Cala to build the clinical evidence and the payment pathway from scratch, through repeated appeals.Microneedle/microarray patches have existed for decades without FDA approval; PinPrint argues the real bottleneck has been manufacturing precision, which high-resolution 3D printing now addresses.🎧 Tune in now to hear how Renee Ryan turned data into dollars in neuromodulation and where she’s taking the body’s next interface with PinPrint.